Journal article
Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers
Drug metabolism and disposition, v 45(2)
Feb 2017
PMID: 27856525
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
From fits of drug transport kinetics across confluent MDCKII-hMDR1-NKI and Caco-2 cell monolayers we estimated the levels of efflux active P-glycoprotein (P-gp) in these two cell lines (companion paper). In the present work, we compared the efflux active P-gp number to the total P-gp level, using liquid chromatography-tandem mass spectrometry, and showed that in Caco-2 cells total P-gp is about 10-fold greater than efflux active P-gp, whereas in MDCKII-hMDR1-NKI cells these values are within twofold. We further visualized the microvilli in MDCKII-hMDR1-NKI and Caco-2 cells using three-dimensional structured illumination super-resolution microscopy and found that the microvilli in Caco-2 cells are taller and more densely packed than those in MDCK-hMDR1-NKI cells. We hypothesized over 10 years ago that only P-gp at the tips of the microvilli contribute significantly to efflux activity, whereas the remaining P-gp are involved in a futile cycle of efflux of amphipathic drugs from the microvillus membrane, followed by their reabsorption into the same or nearby microvillous membranes. The difference between the levels of total and efflux active P-gp in Caco-2 cells can be explained by the more densely packed microvilli in Caco-2 cells, which would lead to a substantial fraction of P-gp not contributing to final release of drug into the apical chamber. Our results suggest that the effect of microvilli morphology differences between in vitro and in vivo systems must be considered when scaling transporter activity for efflux transporters of amphipathic compounds, for example, P-gp.
Metrics
Details
- Title
- Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers
- Creators
- Zhou Meng - Department of Biology, Drexel University, Philadelphia, Pennsylvania (Z.M., S.L.M., D.A., J.B.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (Z.M., M.S., H.E.)Sylvain Le Marchand - Department of Biology, Drexel University, Philadelphia, Pennsylvania (Z.M., S.L.M., D.A., J.B.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (Z.M., M.S., H.E.)Deep Agnani - Department of Biology, Drexel University, Philadelphia, Pennsylvania (Z.M., S.L.M., D.A., J.B.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (Z.M., M.S., H.E.)Matthew Szapacs - Department of Biology, Drexel University, Philadelphia, Pennsylvania (Z.M., S.L.M., D.A., J.B.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (Z.M., M.S., H.E.)Harma Ellens - Department of Biology, Drexel University, Philadelphia, Pennsylvania (Z.M., S.L.M., D.A., J.B.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (Z.M., M.S., H.E.)Joe Bentz - Drexel University
- Publication Details
- Drug metabolism and disposition, v 45(2)
- Publisher
- American Society for Pharmacology and Experimental Therapeutics (ASPET)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Biology
- Web of Science ID
- WOS:000393203400004
- Scopus ID
- 2-s2.0-85011005550
- Other Identifier
- 991019169009504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Pharmacology & Pharmacy